Ask Assistant
Preclinical-stage biotechnology · Montréal
Targeted therapies for autoimmune disease.
Corvin designs therapies that act on a single driver of autoimmune inflammation, rather than dampening the immune system broadly. Every program on this page says the stage it is at, in plain terms.
We are preclinical. Nothing here is in patients, and no program is described as safe or effective. Those are conclusions the data has not yet earned.
Pipeline at a glance
CVT-101
Rheumatoid arthritis
IND-enabling studies
CVT-207
Lupus nephritis
Lead optimization
CVT-3xx
Undisclosed autoimmune
Discovery
Who is building it
Corvin is twelve people, Series A, with a laboratory in the Mile-Ex. The founders and the scientific advisory board have published on the biology the programs are built on. The team and the publication list are named on the Team & Science page.
Team, advisors, and publications →Ask the assistant about a program stage →